Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102512 | 0.85 | CYP11B1 (0.56) | CYP11B1CYP11B2TSHRKIF11MEN1 | |
| SCHEMBL1102875 | 0.84 | CYP11B1 (0.48) | CYP11B1CYP11B2TSHRKIF11MEN1 | |
| SCHEMBL22028062 | 0.82 | ADRA2A (0.38) | CYP11B1CYP11B2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30997743 | 0.82 | ADRA2A (0.38) | CYP11B1CYP11B2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12156777 | 0.82 | ALDH1A1 (0.47) | KIF11SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL1103278 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2TSHRKIF11MEN1 | |
| SCHEMBL18671377 | 0.80 | KIF11 (0.41) | TSHRKIF11MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28663639 | 0.79 | CYP11B1 (0.61) | CYP11B1CYP11B2TSHRMEN1KMT2A | |
| SCHEMBL21117972 | 0.78 | ALOX5 (0.36) | CYP11B1CYP11B2TSHRKIF11MEN1 | |
| SCHEMBL9845507 | 0.78 | CYP11B1 (0.61) | CYP11B1CYP11B2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9893292-B2 | Materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20140203215-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8679645-B2 | Materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20090128009-A1 | Materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-1888707-A1 | NEW MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | Merck Patent GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131192-A1 | NEW MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| JP-2005008600-A | 9,10-BIS(5,6,7,8-TETRAHYDRO-2-NAPHTHYL)ANTHRACENE COMPOUND, METHOD FOR PRODUCING THE SAME AND ORGANIC ELECTROLUMINESCENT ELEMENT | SONY CORP | 2005-01-13 | — | — | JP | disclosed |
| JP-2005008600-A | 9,10-BIS(5,6,7,8-TETRAHYDRO-2-NAPHTHYL)ANTHRACENE COMPOUND, METHOD FOR PRODUCING THE SAME AND ORGANIC ELECTROLUMINESCENT ELEMENT | SONY CORP | 2005-01-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CYP11B1 4077/4885CYP11B2 4488/4885TSHR 4004/4885 |
| US-20090128009-A1 | Materials for organic electroluminescence devices | OR10J3, TYR, EML4 | CYP11B1 3241/4885CYP11B2 2552/4885TSHR 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.